Compare PCYO & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCYO | ACIU |
|---|---|---|
| Founded | 1976 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.5M | 247.6M |
| IPO Year | 1995 | 2015 |
| Metric | PCYO | ACIU |
|---|---|---|
| Price | $10.93 | $2.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 78.1K | ★ 149.7K |
| Earning Date | 04-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.50 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $1,227,787.00 | N/A |
| Revenue This Year | N/A | $706.75 |
| Revenue Next Year | N/A | $321.13 |
| P/E Ratio | $30.19 | ★ N/A |
| Revenue Growth | ★ 171.54 | N/A |
| 52 Week Low | $9.71 | $2.10 |
| 52 Week High | $12.44 | $4.00 |
| Indicator | PCYO | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 41.39 | 42.92 |
| Support Level | $10.46 | $2.13 |
| Resistance Level | $11.03 | $2.68 |
| Average True Range (ATR) | 0.17 | 0.13 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 37.10 | 24.89 |
Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in three business segments namely Water and wastewater resource development, Land development, and the Single-Family Rental Segment. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.